Ruxolitinib (Jakafi)
Jump to navigation
Jump to search
Also formerly known as INCB018424.
General information
Class/mechanism: ATP mimetic JAK1 and JAK2 inhibitor [1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
None available at this time.
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)